Amneal Pharmaceuticals (AMRX) Change in Receivables (2017 - 2026)

Amneal Pharmaceuticals' Change in Receivables history runs 10 years deep, the most recent figure standing at -$44.0 million for Q1 2026.

• In Q1 2026, Change in Receivables fell 108.12% year-over-year to -$44.0 million; the TTM figure through Mar 2026 stood at $97.7 million (up 13.19% YoY), while the FY2025 annual figure was $120.6 million, down 25.87% from the prior year.
• Change in Receivables was -$44.0 million for Q1 2026 at Amneal Pharmaceuticals, down from $10.3 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $129.0 million in Q2 2023 to a low of -$196.0 million in Q1 2023.
• Historically, Change in Receivables has averaged $6.7 million across 5 years, with a median of $17.9 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Change in Receivables tumbled 323.41% in 2023, then soared 455.83% in 2025.
• A 5-year view of Change in Receivables shows it stood at $34.6 million in 2022, then slumped by 323.41% to -$77.2 million in 2023, then surged by 137.04% to $28.6 million in 2024, then sank by 63.86% to $10.3 million in 2025, then tumbled by 525.74% to -$44.0 million in 2026.
• The last three Change in Receivables figures came in at -$44.0 million (Q1 2026), $10.3 million (Q4 2025), and $77.6 million (Q3 2025), per Business Quant data.